about
p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients.A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma.p-Cresol and cardiovascular risk in mild-to-moderate kidney diseaseImpact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled TrialMicrobiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD.Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocritMetabolism, Protein Binding, and Renal Clearance of Microbiota-Derived p-Cresol in Patients with CKD.The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells.Response to 'Tacrolimus pharmacokinetics after kidney transplantation--Influence of changes in haematocrit and steroid dose'.Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.The influence of renal transplantation on retained microbial-human co-metabolites.Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum.Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology.In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.Exploring binding characteristics and the related competition of different protein-bound uremic toxins.A liquid chromatography - tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism.Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.p-Cresol for better or worse: but what are we measuring?The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronideWarning: the unfortunate end of p-cresol as a uraemic toxinApparent elevation of cyclosporine whole blood concentrations in a renal allograft recipientCombined effects of CYP3A5*1, POR*28, and CYP3A4*22 single nucleotide polymorphisms on early concentration-controlled tacrolimus exposure in de-novo renal recipientsAlbumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfateTime course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantationProtein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis
P50
Q33560454-603D56FE-69EF-4BED-BC13-7E3D6EDD5AD3Q33785079-F0864635-0365-4999-AA81-76A6BD24C68EQ33944858-F790A49C-D77D-42A8-9B8E-5B34BA0D2103Q34596313-EEDCC7F8-7D1C-45F6-B377-67F1A2177334Q35995858-A9D1283A-B15E-49CC-B461-ACAE94CD9C68Q36031714-25E8316E-5B19-4F10-9760-9091AD5661F2Q36072508-CD51F2CE-063B-43AA-B478-1B0419266437Q37069948-A4F46A48-7DD4-45EA-A8BE-1612169CC4FAQ38919797-E9DFD954-D387-41F2-AB89-BE0A5AF92913Q42953764-5C1F49F4-E617-4CAD-8C40-60BF83EB193BQ45279289-42FA6630-5D88-4348-B62B-D373B31EEE85Q46579648-5653EEB3-4106-4E79-B7E2-41223CDE37EDQ46582267-27A86526-DA3D-4E69-8ADF-A48AFD2B9F6AQ46616212-9A8E8152-8E38-4B32-A316-7391F80647C8Q46834233-A21C40C3-AC72-4BC8-8C4B-626C90C83642Q47292609-A0EF208F-97EE-4083-BC1B-5AC6AC49D448Q47303894-8AE33729-B108-42BC-A4BE-5B09E1F47C04Q47400761-DDAE3F21-C5A8-409F-A5DC-DE09D1ABF400Q47803890-FAF12340-2E88-405E-ACE1-48FE1F26DDD8Q48247827-07CF32BC-9A72-4060-9504-90ACCDA866A2Q49093312-5B17D971-B572-4090-98CE-D78BC31872C7Q51835993-E6D8DA27-FE52-49A2-A16E-828A03192604Q53171412-50F59F69-E6B8-4C15-9D31-FA1A2A2AE8B5Q79817400-E5894CFA-B279-48B5-B6F4-E58417DD97D2Q80798786-E8479C89-7267-4BE0-ACA6-19EE39FDAF92Q83619794-3B002FA0-80E1-47B9-8B0A-6841588975FEQ84563404-50248E82-9782-45D5-A0CB-B39068EE30D8Q85811327-5F1805DF-A0D3-422F-A1C6-8EB9F95C95F1Q85856578-528FADDF-DF3E-4A24-B753-DBAB297A9EABQ88139167-581BC4AE-A775-44CF-B7E0-1E4401E89EB3Q88147624-0856BDE6-B3D8-4933-8F02-8214D9AB254A
P50
description
researcher ORCID ID = 0000-0003-4421-6340
@en
wetenschapper
@nl
name
Henriette de Loor
@ast
Henriette de Loor
@en
Henriette de Loor
@nl
type
label
Henriette de Loor
@ast
Henriette de Loor
@en
Henriette de Loor
@nl
prefLabel
Henriette de Loor
@ast
Henriette de Loor
@en
Henriette de Loor
@nl
P106
P31
P496
0000-0003-4421-6340